Wczytywanie spółki
Keep exploring
The themes Immix Biopharma is part of, the highest-graded companies in its industry, and the companies in its sector whose grade rose recently.
Highest-graded in Biotechnology
Graded A or B and worth $2B or more: A first, then the largest.
ONCBeone Medicines Ltd.47,6B USDA+
EXELExelixis, Inc.16,8B USDA+
JAZZJazz Pharmaceuticals plc15,5B USDA
TECHBIO-Techne Corp11,4B USDA+
HALOHalozyme Therapeutics, Inc.11,4B USDA+
Grade rose recently in Healthcare
Rose to A or B on a filing in the last 90 days, worth $2B or more: largest first.
DHRDanaher Corporation21 paź 2026CBGraded C, now B
MCKMckesson Corporation4 lis 2026BAGraded B, now A
CVSCVS Health Corp4 lis 2026BAGraded B, now A
EWEdwards Lifesciences Corporation4 lis 2026BAGraded B, now A
GEHCGE Healthcare Technologies Inc.28 paź 2026CAGraded C, now A
Jak zarabia
- No product revenue
Konkuruje z
Co sprzedaje1
NXC-201
A treatment made from a patient’s own immune cells, altered to recognize BCMA on diseased cells. It is being studied mainly for relapsed or treatment-resistant AL amyloidosis.
Na czym się opiera i co może to zburzyć
Od czego zależy ta działalność
- 1Immix depends on raising outside capital and receiving grant reimbursements to pay for research and clinical trials; it has no product sales.
- 2It relies on outside contract manufacturers to make its treatment candidates for studies and any future commercial use.
- 3It relies on a license from Hadasit and BIRAD for intellectual property used in NXC-201, and owes payments under that agreement.
- 4Progress depends on enrolling patients, completing clinical studies, and obtaining regulatory approval before any treatment can be sold.
Co może pójść nie tak
- 1Clinical studies may fail to show that NXC-201 is safe and effective, or regulators may decide the results are not enough to approve it.
- 2Immix has recurring losses and no product revenue, so it must secure further funding; if it cannot, it may have to delay, reduce, or stop development work.
- 3Reliance on outside manufacturers and licensed intellectual property could delay or disrupt development if suppliers fail to meet requirements or license rights are lost.
Pełne sprawozdania finansowe →
O spółce Immix Biopharma, Inc.
Immix is developing chimeric antigen receptor T-cell (CAR-T) treatments, which use a patient’s own immune cells, changed to recognize and attack diseased cells. Its main candidate, NXC-201, is designed to target B-cell maturation antigen (BCMA) on cells involved in light-chain (AL) amyloidosis. Its U.S. study of NXC-201 had enrolled 45 patients by June 30, 2026 (high confidence). Immix has no approved medicines for sale and has not generated revenue from product sales.
- Siedziba
- Los Angeles, California
- Rok założenia
- 2012
- Zatrudnienie
- 21 (March 20, 2026, high)
- Notowana na
- Nasdaq Capital Market
- Koniec roku obrotowego
- December 31
Zbudowane z własnych raportów spółki Immix Biopharma, Inc. składanych do amerykańskiej Komisji Papierów Wartościowych i Giełd (SEC). Liczby są takie, jak zaraportowano, a historia na akcję przeliczona na dzisiejszą bazę akcji. To opisuje firmę — nie jest poradą inwestycyjną ani rekomendacją kupna lub sprzedaży.
